Clinical Trial Update: A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 study evaluating the combination of Spartalizumab and Canakinumab in localized clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Canakinumab (canakinumab)
• Spartalizumab (spartalizumab)

Snippet

Sponsor: Columbia University | Conditions: Carcinoma, Renal Cell | EARLY_Phase 1 | Status: COMPLETED